Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Study limitation reported by the research below: “Level of evidence set to 5 (expert opinion/consensus), consistent with modified Delphi methodology without empirical outcome data.”